In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data

Executive Summary

ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.

Related Content

A Few Companies Bet On Continuing Role For Interferon Therapy In HCV
Biogen Idec Charts A New Course
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
Shire Emphasizes The GI Space In Its Bid For Movetis
BMS Files Ipilimumab With FDA And EMA, Positioning It For Launch Next Year
No Joy In Bayer/Onyx’s Phase III With Nexavar For Melanoma
Elesclomol’s Phase III Fizzle Leaves Synta In Need of Plan B
Weak Result Stops Pfizer’s Tremelimumab Phase III Trial
Novo-ZymoGenetics: The Next Roche-Genentech?


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts